Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Pfizer Inc — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $116.59, while Pfizer Inc trades at $24.88 (market cap $141.06B). The key difference: Pfizer Inc pays a 6.95% dividend while iShares 3 7 Year Treasury Bond ETF pays none, and Pfizer Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEI | PFE | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $120.72 | $28.56 |
52-Week Low | $116.45 | $23.29 |
Market Cap | — | $141.06B |
Volume | — | 29,869,932 |
Enterprise Value | — | $191.72B |
Dividend Yield | — | 6.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI (iShares 3-7 Year Treasury Bond ETF) trades at $116.76, down 0.19% with a bearish technical signal. Recent dividends include $0.36 and $0.37 payouts in mid-2026. The ETF faces headwinds from rising Treasury yields and Federal Reserve uncertainty, as bond markets react to inflation and geopolitical tensions.
Outlook remains cautious due to interest rate sensitivity; opportunities exist for low-volatility Treasury exposure, but risks include further Fed hikes and competitive pressure from higher-yielding bond ETFs like Vanguard's offerings.
Pfizer (PFE) trades at $25.05, down 0.36% on the day, with a bullish technical signal supported by strong quarterly earnings beats. The company maintains solid profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated post-pandemic. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning PFE for potential growth catalysts in 2026.
The outlook for Pfizer is cautiously optimistic, with a consensus price target of $28.25 offering 13% upside. Key opportunities include dividend stability and pipeline innovation, while risks involve patent cliffs and competitive pressures. Analyst sentiment is mixed with 38% buy ratings, reflecting balanced views on recovery potential versus near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
